Burning Rock Biotech (BNR) Non-Current Receivables (2022 - 2024)
Historic Non-Current Receivables for Burning Rock Biotech (BNR) over the last 5 years, with Q3 2024 value amounting to $758000.0.
- Burning Rock Biotech's Non-Current Receivables rose 828.57% to $758000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $758000.0, marking a year-over-year increase of 828.57%. This contributed to the annual value of $749000.0 for FY2023, which is 121.62% up from last year.
- As of Q3 2024, Burning Rock Biotech's Non-Current Receivables stood at $758000.0, which was up 828.57% from $732000.0 recorded in Q2 2024.
- Burning Rock Biotech's 5-year Non-Current Receivables high stood at $758000.0 for Q3 2024, and its period low was $32000.0 during Q4 2020.
- Its 5-year average for Non-Current Receivables is $532615.4, with a median of $704000.0 in 2023.
- Its Non-Current Receivables has fluctuated over the past 5 years, first skyrocketed by 36866.67% in 2022, then tumbled by 80.75% in 2024.
- Quarter analysis of 5 years shows Burning Rock Biotech's Non-Current Receivables stood at $32000.0 in 2020, then soared by 368.75% to $150000.0 in 2021, then soared by 393.33% to $740000.0 in 2022, then grew by 1.22% to $749000.0 in 2023, then rose by 1.2% to $758000.0 in 2024.
- Its Non-Current Receivables was $758000.0 in Q3 2024, compared to $732000.0 in Q2 2024 and $737000.0 in Q1 2024.